LOGIN  |  REGISTER
Assertio
C4 Therapeutics

Oscar Health to Present at Upcoming Healthcare Conferences

August 22, 2024 | Last Trade: US$12.35 0.10 -0.80

NEW YORK / Aug 22, 2024 / Business Wire / Oscar Health, Inc. (“Oscar”) (NYSE: OSCR), a leading healthcare technology company, today announced its leaders will present and provide a business update at three upcoming healthcare conferences:

  • 2024 Wells Fargo Healthcare Conference: Chief Financial Officer, Scott Blackley, will participate in a fireside chat at approximately 12:45 p.m. ET on September 4, 2024.
  • Morgan Stanley 22nd Annual Global Healthcare Conference: Chief Executive Officer, Mark Bertolini, will participate in a fireside chat at approximately 1:50 p.m. ET on September 5, 2024.
  • Baird 2024 Global Healthcare Conference: Chief Financial Officer, Scott Blackley, will participate in a fireside chat at approximately 2:35 p.m. ET on September 11, 2024.

All interested parties are invited to listen to a live webcast by visiting ir.hioscar.com and selecting the “Events & Presentations” link. Following each presentation, a webcast replay will be available on Oscar’s investor relations website for 90 days.

About Oscar Health

Oscar Health, Inc. (“Oscar”) is a leading healthcare technology company built around a full stack technology platform and a relentless focus on serving our members. We have been challenging the status quo in the healthcare system since our founding in 2012, and are dedicated to making a healthier life accessible and affordable for all. Oscar offers Individual & Family plans and health technology solutions that power the healthcare industry through +Oscar. Our technology drives superior experiences, deep engagement, and high-value clinical care, earning us the trust of approximately 1.6 million members, as of June 30, 2024.

For more information, please visit www.hioscar.com.

Viking Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page